We investigated whether the competitive mGlu1 antagonist LY367385 or the non-competitive mGlu1 antagonist Bay 36-7620 could inhibit the proliferation of mGlu1 positive C8161 human melanoma cells. Here, GRM1 is linked to melanoma.